Capital World Investors Has $228.34 Million Holdings in Grifols, S.A. $GRFS

Capital World Investors grew its holdings in Grifols, S.A. (NASDAQ:GRFS) by 5.9% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 22,926,140 shares of the biotechnology company’s stock after acquiring an additional 1,273,391 shares during the quarter. Capital World Investors’ holdings in Grifols were worth $228,344,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of GRFS. Versant Capital Management Inc grew its stake in shares of Grifols by 39.5% in the third quarter. Versant Capital Management Inc now owns 5,598 shares of the biotechnology company’s stock worth $56,000 after acquiring an additional 1,584 shares during the last quarter. Peterson Wealth Services boosted its holdings in Grifols by 385.8% in the 3rd quarter. Peterson Wealth Services now owns 7,287 shares of the biotechnology company’s stock valued at $73,000 after purchasing an additional 5,787 shares during the period. EverSource Wealth Advisors LLC grew its position in Grifols by 127.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 8,219 shares of the biotechnology company’s stock worth $74,000 after purchasing an additional 4,604 shares during the last quarter. PNC Financial Services Group Inc. grew its position in Grifols by 109.8% in the 3rd quarter. PNC Financial Services Group Inc. now owns 8,634 shares of the biotechnology company’s stock worth $86,000 after purchasing an additional 4,518 shares during the last quarter. Finally, Ameriprise Financial Inc. bought a new position in shares of Grifols during the 2nd quarter worth about $95,000.

Grifols Trading Down 2.1%

Shares of GRFS opened at $8.03 on Thursday. The company has a current ratio of 2.51, a quick ratio of 0.88 and a debt-to-equity ratio of 1.20. The stock has a fifty day moving average price of $9.13 and a two-hundred day moving average price of $9.25. Grifols, S.A. has a 52-week low of $6.19 and a 52-week high of $11.14.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on GRFS shares. Wall Street Zen cut shares of Grifols from a “buy” rating to a “hold” rating in a research note on Sunday. JPMorgan Chase & Co. lowered their price target on Grifols from $10.30 to $10.00 and set a “neutral” rating on the stock in a research note on Monday, December 8th. Zacks Research upgraded Grifols from a “strong sell” rating to a “hold” rating in a research report on Friday, February 6th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Grifols in a research note on Thursday, January 22nd. Four investment analysts have rated the stock with a Hold rating, Based on data from MarketBeat, Grifols currently has a consensus rating of “Hold” and a consensus target price of $10.00.

Grifols Profile

Grifols, Inc (NASDAQ: GRFS) is a global healthcare company specializing in the development, manufacture and marketing of plasma-derived medicines, diagnostic systems and hospital supplies. With a core focus on immunotherapy and transfusion medicine, the company harnesses human plasma proteins to create therapies that treat a wide range of bleeding disorders, immunodeficiencies and neurological conditions. Grifols also supplies reagents and diagnostic instruments for transfusion centers and clinical laboratories, alongside intravenous solutions and medical devices for hospital use.

The company operates three main business units.